KAIROS PHARMA, LTD. (NYSE: KAPA)

NYSE: KAPA (Kairos Pharma, Ltd.)

Kemas kini terakhir: 04 Apr, 11:55AM

0.20 (21.27%)

Tambah ke senarai pantauan

Harga / Buku (P/B)

3.87

Julat 52 Minggu

0.851 (-25%) — 4.00 (250%)

Arah Aliran Pasaran

AISkor Stockmoo

-0.4

Saham Serupa

Stok	Modal Pasaran	DY	P/E (TTM)	P/B
KAPA	16 M	-	-	3.87
PLX	186 M	-	59.75	4.68
CYBN	114 M	-	-	0.710
LCTX	99 M	-	-	1.22
ANRO	71 M	-	-	0.360
SER	48 M	-	30.63	78.09

Kairos Pharma, Ltd. operates as a clinical-stage biopharmaceutical company that develops therapeutics for cancer patients. Its therapeutics include antibodies and small molecules for the treatment of prostate cancer, lung cancer, breast cancer, and glioblastoma. Kairos Pharma, Ltd. was formerly known as NanoGB13, Inc. and changed its name to Kairos Pharma, Ltd. in July 2016. The company was incorporated in 2013 and is based in Los Angeles, California.
Sektor	Healthcare
Industri	Biotechnology
% Dimiliki oleh Orang Dalam	57.51%
% Dimiliki oleh Institusi	2.98%

Pemilikan

Nama	Tarikh	Syer Dipegang
Umb Bank, N.A.	31 Dec 2024	371,115

Tiada data dalam julat masa ini.

Tarikh	Jenis	Butiran
31 Mar 2025	Pengumuman	Kairos Pharma Ltd. Announces Completed Enrollment of the Safety Arm of Its Phase 2 Clinical Trial of ENV105 in Metastatic, Castration-Resistant Prostate Cancer
28 Mar 2025	Pengumuman	CEO.CA's Inside the Boardroom: Kairos Pharma's Breakthrough Cancer Treatment & What's Next for ENV105
27 Mar 2025	Pengumuman	Kairos Pharma Ltd. Highlights Participation in Recent and Upcoming Scientific and Industry Events
20 Mar 2025	Pengumuman	Kairos Pharma Ltd. Announces Peer Reviewed Publication Highlighting Potentially Groundbreaking Discovery in Overcoming Drug Resistance in Non-Small Cell Lung Cancer
26 Feb 2025	Pengumuman	Kairos Pharma Presents Preclinical Data on its Investigational Compounds KROS 101 and KROS 401 Further Supporting Both Compounds’ Potential as Therapeutics for Melanoma and Glioblastoma
18 Feb 2025	Pengumuman	Kairos Pharma Announces New Department of Defense Funding for Research of ENV205
11 Feb 2025	Pengumuman	Kairos Pharma Adds Huntsman Cancer Institute for Phase 2 ENV105 Clinical Trial
06 Feb 2025	Pengumuman	Kairos Pharma Oral Presentation on Its Investigational Compound KROS 101 at the 13th AACR-JCA Joint Conference Supports the Compound’s Potential as a Therapeutic for Melanoma and Glioblastoma
28 Jan 2025	Pengumuman	Kairos Pharma to Present Short Talk on Its Investigational Compound KROS 101 at the 13th AACR-JCA Joint Conference February 5, 2024
21 Jan 2025	Pengumuman	Kairos Pharma Provides Business Update and Outlook into 2025

Portfolio

AI Templat

Peringatan harga anda

Harga Masuk (EP)

Ambil Untung 1 (TP1)

Ambil Untung 2 (TP2)

Henti Rugi (SL)

Tiada saham yang memenuhi kriteria anda

Jumlah Hutang/Ekuiti (D/E MRQ)	4.26%
Nisbah Semasa (MRQ)	2.84
Aliran Tunai Operasi (OCF TTM)	-2.09 M
Aliran Tunai Bebas Leveraj (LFCF TTM)	-3.52 M

Pulangan Atas Aset (ROA TTM)	-41.71%
Pulangan Atas Ekuiti (ROE TTM)	-375.74%